000423.SZ
东阿阿胶
SZSE · Healthcare · C 制造业 · CN
CNY 48.00
−0.72%Year over year
Reported trailing growth
- Revenue
- +5.8%
- EBITDA
- —
- EBIT
- +8.3%
- EPS
- +8.5%
- Free cash flow
- +37.7%
- Operating cash flow
- +37.1%
Forward estimates
Based on analyst estimates
- Revenue
- +21.3%
- EBITDA
- +22.3%
- EPS
- +18.6%
Three-year CAGR
- Revenue
- +18.4%
- EBITDA
- +27.5%
- EBIT
- +31.3%
- Net income
- +30.6%
- EPS
- +30.7%
- Free cash flow
- +1.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026